Celebrating 25 years Est 1999-2024
*Across 3 years $2276.64 only $796.82
(Updates with premarket stock moves, company's description of primary endpoint) DOW JONES NEWSWIRES Seattle Genetics Inc. (SGEN) ended a midstage...
("=Seattle Genetics Ends Trial Of Cancer Drug >SGEN," published at 7:34 a.m. EDT, misstated Friday's closing share price and the percent change...
Seattle Genetics Inc. (SGEN) ended a midstage trial, saying its cancer drug dacetuzumab didn't look likely to meet the main goal of the test. The...
Bristol-Myers Squibb Co.'s (BMY) $2.1 billion purchase of Medarex Inc. (MEDX), with a premium exceeding 90%, demonstrates that companies...
American Stock Exchange to Trade Options on Eight Securities NEW YORK, Aug. 31 /PRNewswire/ -- The American Stock Exchange(R) (Amex(R)) will...
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.